The fourth edition of Building Biotechnology, the premier biotechnology industry primer, is now available. Building Biotechnology has been adopted by dozens of […]

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Embryo and stem cell research: Views from the USA
Go to paperABSTRACT: Presents a study that examined the history, ethical debates and religious views rega…

With prior BiotechBlog intern Fintan Burke moving on to some exciting new projects, I have time to train a few

Ananda Chakrabarty is the holder of the first patent on a genetically-modified organism. Lately he’s turned his sights to a

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
Go to paperABSTRACT: The two leading therapeutic areas for biological products, in t…

The fourth edition of Building Biotechnology, the premier biotechnology industry primer, is slated for publication in December and is ready for reviewers.

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Forecasting new product revenues
Go to paperABSTRACT: This paper discusses real-life experiences in developing revenue forecasts for biopharmaceutical clien…

Made available by the elective open access option at the Journal of Commercial Biotechnology, this paper is free to view without subscription: Assessing